What to expect when you take Navelbine and have Bone loss?

Do you take Navelbine and have Bone loss? Find out below what new side effects and undetected conditions people who are 50-59 years old may have. This prediction is created after we perform predictive analysis on health care big data. It will be updated regularly.

To personalize this prediction to you, including to your gender, age, personal and family history, and more: Click here



On May, 24, 2018

1,671 reports have been studied.


Females aged 50 to 59 :

1,160 related reports were analyzed:

Most common symptoms:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  • 9.48% for females aged 50 (±5) who take Navelbine
Anaemia (lack of blood)
  • 12.16% for females aged 50 (±5) who take Navelbine
Appetite - decreased (decreased appetite occurs when you have a reduced desire to eat)
  • 5.26% for females aged 50 (±5) who take Navelbine
Aseptic necrosis (the death of bone tissue due to a lack of blood supply)
  • 9.4% for females aged 50 (±5) who take Navelbine
Atelectasis (partial or complete collapse of the lung)
  • 6.55% for females aged 50 (±5) who take Navelbine
Back pain
  • 10.34% for females aged 50 (±5) who take Navelbine
Bone disorder
  • 13.02% for females aged 50 (±5) who take Navelbine
Bone pain
  • 6.64% for females aged 50 (±5) who take Navelbine
Chest pain
  • 6.98% for females aged 50 (±5) who take Navelbine
Constipation
  • 8.79% for females aged 50 (±5) who take Navelbine
Cough
  • 5.09% for females aged 50 (±5) who take Navelbine
Death
  • 6.03% for females aged 50 (±5) who take Navelbine
Decreased interest
  • 5.17% for females aged 50 (±5) who take Navelbine
Depression
  • 5.0% for females aged 50 (±5) who take Navelbine
Diarrhea
  • 8.1% for females aged 50 (±5) who take Navelbine
Dizziness
  • 8.53% for females aged 50 (±5) who take Navelbine
Dyspnea (difficult or laboured breathing)
  • 16.47% for females aged 50 (±5) who take Navelbine
Fall
  • 5.95% for females aged 50 (±5) who take Navelbine
Fatigue (feeling of tiredness)
  • 12.07% for females aged 50 (±5) who take Navelbine
Fever
  • 16.21% for females aged 50 (±5) who take Navelbine
Gastroesophageal reflux disease (a condition in which stomach contents leak backward from the stomach into the oesophagus)
  • 5.43% for females aged 50 (±5) who take Navelbine
General physical health deterioration (weak health status)
  • 6.12% for females aged 50 (±5) who take Navelbine
Headache (pain in head)
  • 6.47% for females aged 50 (±5) who take Navelbine
High blood pressure
  • 6.98% for females aged 50 (±5) who take Navelbine
Hypoaesthesia (reduced sense of touch or sensation)
  • 8.71% for females aged 50 (±5) who take Navelbine
Impaired healing
  • 8.45% for females aged 50 (±5) who take Navelbine
Infection
  • 5.17% for females aged 50 (±5) who take Navelbine
Injury
  • 7.59% for females aged 50 (±5) who take Navelbine
Joint pain
  • 9.14% for females aged 50 (±5) who take Navelbine
Malignant neoplasm progression (cancer tumour came back)
  • 6.64% for females aged 50 (±5) who take Navelbine
Metastases to bone (cancer spreads to bone)
  • 11.12% for females aged 50 (±5) who take Navelbine
Metastases to central nervous system (cancer spreads to central nervous system)
  • 6.55% for females aged 50 (±5) who take Navelbine
Metastases to liver (cancer spreads to liver)
  • 7.76% for females aged 50 (±5) who take Navelbine
Metastases to lung (cancer spreads to lung)
  • 8.1% for females aged 50 (±5) who take Navelbine
Nausea (feeling of having an urge to vomit)
  • 12.16% for females aged 50 (±5) who take Navelbine
Neoplasm malignant (cancer tumour)
  • 5.95% for females aged 50 (±5) who take Navelbine
Oedema peripheral (superficial swelling)
  • 6.72% for females aged 50 (±5) who take Navelbine
Oral disorder (mouth disease)
  • 6.29% for females aged 50 (±5) who take Navelbine
Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  • 6.12% for females aged 50 (±5) who take Navelbine
Osteomyelitis (infection of bone)
  • 8.71% for females aged 50 (±5) who take Navelbine
Osteonecrosis of jaw (death of bone of jaw)
  • 15.34% for females aged 50 (±5) who take Navelbine
Pain
  • 17.59% for females aged 50 (±5) who take Navelbine
Pain in jaw
  • 6.9% for females aged 50 (±5) who take Navelbine
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  • 6.81% for females aged 50 (±5) who take Navelbine
Pleural effusion (water on the lungs)
  • 10.43% for females aged 50 (±5) who take Navelbine
Pneumonia
  • 5.86% for females aged 50 (±5) who take Navelbine
Rashes (redness)
  • 7.33% for females aged 50 (±5) who take Navelbine
Spinal osteoarthritis (joint cartilage loss in spine)
  • 6.55% for females aged 50 (±5) who take Navelbine
Stomatitis (inflammation of mucous membrane of mouth)
  • 5.69% for females aged 50 (±5) who take Navelbine
Stress and anxiety
  • 14.48% for females aged 50 (±5) who take Navelbine
Swelling
  • 6.81% for females aged 50 (±5) who take Navelbine
Thrombocytopenia (decrease of platelets in blood)
  • 6.29% for females aged 50 (±5) who take Navelbine
Tooth extraction
  • 9.66% for females aged 50 (±5) who take Navelbine
Toothaches (tooth pain)
  • 6.98% for females aged 50 (±5) who take Navelbine
Urinary tract infection
  • 5.09% for females aged 50 (±5) who take Navelbine
Weakness
  • 10.69% for females aged 50 (±5) who take Navelbine
Weight decreased
  • 6.64% for females aged 50 (±5) who take Navelbine

Most common co-existing conditions:

Breast cancer metastatic
  • 16.64% for females aged 50 (±5) who take Navelbine
Metastases to bone (cancer spreads to bone)
  • 13.62% for females aged 50 (±5) who take Navelbine
back to top

Males aged 50 to 59 :

511 related reports were analyzed:

Most common symptoms:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  • 16.44% for males aged 50 (±5) who take Navelbine
Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight)
  • 5.09% for males aged 50 (±5) who take Navelbine
Back pain
  • 5.68% for males aged 50 (±5) who take Navelbine
Chest pain
  • 6.65% for males aged 50 (±5) who take Navelbine
Cough
  • 6.26% for males aged 50 (±5) who take Navelbine
Dehydration (dryness resulting from the removal of water)
  • 5.87% for males aged 50 (±5) who take Navelbine
Diarrhea
  • 5.09% for males aged 50 (±5) who take Navelbine
Dyspnea (difficult or laboured breathing)
  • 6.46% for males aged 50 (±5) who take Navelbine
Fever
  • 19.18% for males aged 50 (±5) who take Navelbine
Haemoglobin decreased
  • 5.87% for males aged 50 (±5) who take Navelbine
Nausea (feeling of having an urge to vomit)
  • 6.85% for males aged 50 (±5) who take Navelbine
Pneumonia
  • 5.09% for males aged 50 (±5) who take Navelbine
Thrombocytopenia (decrease of platelets in blood)
  • 8.81% for males aged 50 (±5) who take Navelbine
Weakness
  • 6.65% for males aged 50 (±5) who take Navelbine

Most common co-existing conditions:

Lung cancer - non-small cell (lung cancer)
  • 12.52% for males aged 50 (±5) who take Navelbine
back to top

Related studies

navelbine

Navelbine has active ingredients of vinorelbine tartrate. It is often used in breast cancer. (latest outcomes from Navelbine 7,203 users)

bone loss

Bone loss has been reported by people with osteoporosis, osteopenia, rheumatoid arthritis, high blood pressure, gastroesophageal reflux disease (latest reports from 3,671 Bone loss patients).

Navelbine and Bone loss

Analysis tools (to study 685 million drug outcomes from FDA)

  • Check symptoms - identify the cause of a symptom: from a drug or from a condition?
  • Check drugs - find out common side effects or drug interactions of my drugs.
  • Compare drugs - compare the side effects and efficacy of multiple drugs side by side.

You are not alone. Join our personalized support groups:

Can you answer these questions

More questions for: Navelbine, Bone loss

You may be interested in these posts

More posts for: Navelbine, Bone loss

Recent updates

General studies
Active Support Groups
Recent Predictions
Personalized studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on ePatient.care is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the ePatient.care site and its content is at your own risk.